CD274 and cancer: In particular, ICIs have demonstrated activity in patients with TNBC in the metastatic setting if administered in combination with first-line chemotherapy in patients with programmed death ligand 1 (PD-L1) positive cancers and in the early setting in combination with neoadjuvant chemotherapy, regardless of PD-L1 status [5].